Molecular and biologic biomarkers of Ewing sarcoma: A systematic review

Daher, Mohammad; Zalaquett, Ziad; Chalhoub, Ralph; Farraj, Sami Abi; Abdo, Majd; Sebaaly, Amer; Kourie, Hampig-Raphaël; Ghanem, Ismat

doi:10.1016/j.jbo.2023.100482

Cited by 6 publications

(4 citation statements)

References 78 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For sarcoma, factors such as tumor size, anatomic location, surgical margins, presence of tumor necrosis, intravascular growth, and cell division rate are consulted. In addition, omic studies suggested genes, transcripts, and proteins as prognostic biomarkers [76][77][78]. Three sarcoma MALDI imaging studies identified prognostic signatures based on metabolites (#10), proteins (#7), and N-glycans (#11).…”

Section: Identification Of Prognostic Biomarker Candidatesmentioning

confidence: 99%

Advancing rare cancer research by MALDI mass spectrometry imaging: Applications, challenges, and future perspectives in sarcoma

Stillger,

Li,

Hönscheid

et al. 2024

Proteomics

View full text Add to dashboard Cite

MALDI mass spectrometry imaging (MALDI imaging) uniquely advances cancer research, by measuring spatial distribution of endogenous and exogenous molecules directly from tissue sections. These molecular maps provide valuable insights into basic and translational cancer research, including tumor biology, tumor microenvironment, biomarker identification, drug treatment, and patient stratification. Despite its advantages, MALDI imaging is underutilized in studying rare cancers. Sarcomas, a group of malignant mesenchymal tumors, pose unique challenges in medical research due to their complex heterogeneity and low incidence, resulting in understudied subtypes with suboptimal management and outcomes.In this review, we explore the applicability of MALDI imaging in sarcoma research, showcasing its value in understanding this highly heterogeneous and challenging rare cancer. We summarize all MALDI imaging studies in sarcoma to date, highlight their impact on key research fields, including molecular signatures, cancer heterogeneity, and drug studies. We address specific challenges encountered when employing MALDI imaging for sarcomas, and propose solutions, such as using formalin‐fixed paraffin‐embedded tissues, and multiplexed experiments, and considerations for multi‐site studies and digital data sharing practices.Through this review, we aim to spark collaboration between MALDI imaging researchers and clinical colleagues, to deploy the unique capabilities of MALDI imaging in the context of sarcoma.

show abstract

Section: Identification Of Prognostic Biomarker Candidatesmentioning

confidence: 99%

Advancing rare cancer research by MALDI mass spectrometry imaging: Applications, challenges, and future perspectives in sarcoma

Stillger,

Li,

Hönscheid

et al. 2024

Proteomics

View full text Add to dashboard Cite

show abstract

“…The primary tumor occurs in bones (pelvis, femur, tibia, and ribs) or soft tissues (thoracic wall, gluteal muscle, pleural cavities, and cervical muscles). EwS possesses one of the lowest mutation rates among cancers [ 44 ]. The main drivers are pathognomonic chromosomal translocations resulting in the fusion of members of the FET and ETS families; the former are RNA-binding proteins encoded by FUS , EWSR1 , and TAF15 genes and involved in transcription and splicing; the latter are transcription factors involved in cell proliferation, cell differentiation, cell-cycle control, angiogenesis, and apoptosis.…”

Section: Sarcomasmentioning

confidence: 99%

B7-H3 in Pediatric Tumors: Far beyond Neuroblastoma

Bottino

Vitale

Dondero

et al. 2023

Cancers

View full text Add to dashboard Cite

B7-H3 is a 4Ig transmembrane protein that emerged as a tumor-associated antigen in neuroblastoma. It belongs to the B7 family, shows an immunoregulatory role toward NK and T cells, and, therefore, has been included in the growing family of immune checkpoints. Besides neuroblastoma, B7-H3 is expressed by many pediatric cancers including tumors of the central nervous system, sarcomas, and acute myeloid leukemia. In children, particularly those affected by solid tumors, the therapeutic protocols are aggressive and cause important life-threatening side effects. Moreover, despite the improved survival observed in the last decade, a relevant number of patients show therapy resistance and fatal relapses. Immunotherapy represents a new frontier in the cure of cancer patients and the targeting of tumor antigens or immune checkpoints blockade showed exciting results in adults. In this encouraging scenario, researchers and clinicians are exploring the possibility to use immunotherapeutics targeting B7-H3; these include mAbs and chimeric antigen receptor T-cells (CAR-T). These tools are rapidly evolving to improve the efficacy and decrease the unwanted side effects; drug-conjugated mAbs, bi–tri-specific mAbs or CAR-T, and, very recently, NK cell engagers (NKCE), tetra-specific molecules engaging a tumor-associated antigen and NK cells, have been generated. Preclinical data are promising, and clinical trials are ongoing. Hopefully, the B7-H3 targeting will provide important benefits to cancer patients.

show abstract

“…Despite the adoption of multidrug chemotherapy, long-term OS survival rates for focal lesions have stagnated at >60 % since the 1980s [9] . Targeted therapies have recently emerged as drugs that target weaknesses more particular to malignant cells compared to standard chemotherapy [10] , such as tyrosine kinase receptors (RTKs), which regulate a variety of processes, including cellular growth and differentiation. Tyrosine kinase inhibitors (TKIs) are a family of targeted therapy molecules that selectively target tyrosine kinase receptors and impede the binding of the ligand molecule, thus preventing the activation of downstream pathways [11] , [12] .…”

Section: Introductionmentioning

confidence: 99%

Tyrosine kinase inhibitors in osteosarcoma: Adapting treatment strategiesa

Assi,

Farhat,

Hachem

et al. 2023

Journal of Bone Oncology

Self Cite

View full text Add to dashboard Cite

Molecular and biologic biomarkers of Ewing sarcoma: A systematic review

Cited by 6 publications

References 78 publications

Advancing rare cancer research by MALDI mass spectrometry imaging: Applications, challenges, and future perspectives in sarcoma

Advancing rare cancer research by MALDI mass spectrometry imaging: Applications, challenges, and future perspectives in sarcoma

B7-H3 in Pediatric Tumors: Far beyond Neuroblastoma

Tyrosine kinase inhibitors in osteosarcoma: Adapting treatment strategiesa

Contact Info

Product

Resources

About